Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX4 plus weekly versus bi-weekly cetuximab in first-line metastatic colorectal cancer
2006-006941-15Phase 2Completed
- Sponsor
- Central European Cooperative Oncology Group
- Start
- Jun 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Central European Cooperative Oncology Group. Primary endpoint: Objective response rate by RECIST. Started Jun 2007; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2006-006941-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006941-15.